Bial   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Trofa Portugal (1924)

Organization Overview

First Clinical Trial
2000
NCT02763787
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Bial Portela | BIAL - Portela & Ca S.A. | BIAL - Portela & Ca, S.A | BIAL - Portela & Ca. SA | Bial - Portela C S.A. | Bial R&D Investments, S.A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 1)

Diabetic Neuropathies (Phase 3)

Disease (Phase 2)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 4)

Familial Primary Pulmonary Hypertension (Phase 2)

Fibromyalgia (Phase 2)

Heart Failure (Phase 1)

Hypertension (Phase 2)

Migraine Disorders (Phase 2)

Myofascial Pain Syndromes (Phase 2)

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Pain (Phase 2)

Parkinson Disease (Phase 4)

Peripheral Nervous System Diseases (Phase 2)

Recurrence (Phase 2)

Seizures (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 132
  • # of Trial APIs: 33